StreetInsider.com News Articles

Form S-8 INVO Fertility, Inc.

Fri, 28 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260828/26998641.html

Form S-8 INVO Fertility, Inc.

Fri, 28 Aug 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260828/26998641.html

Form 8-K INVO Fertility, Inc. For: Aug 28

Fri, 28 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260828/26993362.html

Form 8-K INVO Fertility, Inc. For: Aug 28

Fri, 28 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260828/26993362.html

INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Fri, 28 Aug 2026 08:30:00 -0400

SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14 through September 16, 2026, at the Lotte New York Palace Hotel in New York City.

A pre-recorded presentation from the Company will be available on demand as a part of the conference beginning Friday, September 11, 2026, at 7:00 a.m. ET.

INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Fri, 28 Aug 2026 08:30:00 -0400

A pre-recorded presentation from the Company will be available on demand as a part of the conference beginning Friday, September 11, 2026, at 7:00 a.m. ET.

INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Fri, 28 Aug 2026 08:30:00 -0400

A pre-recorded presentation from the Company will be available on demand as a part of the conference beginning Friday, September 11, 2026, at 7:00 a.m. ET.

INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Fri, 28 Aug 2026 08:30:00 -0400

A pre-recorded presentation from the Company will be available on demand as a part of the conference beginning Friday, September 11, 2026, at 7:00 a.m. ET.

INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International

Thu, 20 Aug 2026 09:00:00 -0400

SARASOTA, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that Gretchen Collins, M.D., of the Company's Wisconsin-based clinic, Wisconsin Fertility Institute, presented five poster abstracts at the 2026 Midwest Reproductive Symposium international ("MRSi"), held on July 26-29, 2026, at The Drake Hotel in Chicago, Illinois. This year's meeting theme was "In Full Bloom – The Future of IVF."

Dr. Collins is a double board-certified obstetrician-gynecologist and reproductive

INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International

Thu, 20 Aug 2026 09:00:00 -0400

Dr. Collins is a double board-certified obstetrician-gynecologist and reproductive

INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International

Thu, 20 Aug 2026 09:00:00 -0400

Dr. Collins is a double board-certified obstetrician-gynecologist and reproductive

INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International

Thu, 20 Aug 2026 09:00:00 -0400

Dr. Collins is a double board-certified obstetrician-gynecologist and reproductive

Form 8-K INVO Fertility, Inc. For: Aug 17

Mon, 17 Aug 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260817/26935422.html

Form 8-K INVO Fertility, Inc. For: Aug 17

Mon, 17 Aug 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260817/26935422.html

INVO Fertility (IVF) Tops Q2 EPS by 105c

Mon, 17 Aug 2026 08:33:31 -0400

INVO Fertility (NASDAQ: IVF) reported Q2 EPS of $0.35, $1.05 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $2.17 million versus the consensus estimate of $2.4 million.

For earnings history and earnings-related data on INVO Fertility (IVF) click here.

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Mon, 17 Aug 2026 08:30:00 -0400

Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices

Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses

SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.

Q2 2026 Financial Highlights (all metrics compared

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Mon, 17 Aug 2026 08:30:00 -0400

Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices

Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses

SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.

Q2 2026 Financial Highlights (all metrics compared

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Mon, 17 Aug 2026 08:30:00 -0400

Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices

Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses

SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.

Q2 2026 Financial Highlights (all metrics compared

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Mon, 17 Aug 2026 08:30:00 -0400

Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices

Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses

SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.

Q2 2026 Financial Highlights (all metrics compared

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Mon, 17 Aug 2026 08:30:00 -0400

Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices

Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses

SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.

Q2 2026 Financial Highlights (all metrics compared

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Mon, 17 Aug 2026 08:30:00 -0400

Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices

Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses

SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.

Q2 2026 Financial Highlights (all metrics compared

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Mon, 17 Aug 2026 08:30:00 -0400

Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices

Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses

SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.

Q2 2026 Financial Highlights (all metrics compared

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Mon, 17 Aug 2026 08:30:00 -0400

Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices

Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses

SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.

Q2 2026 Financial Highlights (all metrics compared

Form 10-Q INVO Fertility, Inc. For: Jun 30

Fri, 14 Aug 2026 17:28:00 -0400
si-local-file:///var/storage/secattach/20260814/26932918.html

Form 10-Q INVO Fertility, Inc. For: Jun 30

Fri, 14 Aug 2026 17:28:00 -0400
si-local-file:///var/storage/secattach/20260814/26932918.html